Abstract
Disease caused by Coccidioides immitis has increased in frequency in recent years because of marked population shifts into highly endemic areas, as well as perturbations of the environment caused by construction, agricultural, and natural activities. Because disease may occur in persons in locations outside of the endemic regions, practitioners must be aware of the possibility of infection in those who may have traveled or resided in areas of risk. Recently, advances in laboratory methods have facilitated diagnosis of coccidioidomycosis, and information about therapies that are easier to administer has become available. Challenges in the management of this infection still remain, particularly with regard to more reliable antifungal drugs and protective vaccines.
Similar content being viewed by others
References and Recommended Reading
Stevens DA: Coccidioidomycosis. N Engl J Med 1995, 332:1077–1082.
Chaturvedi V, Ramani R, Gromadzki S, et al.: Coccidioidomycosis in New York state. Emerg Infect Dis 2000, 6:25–29.
Cairns L, Blythe D, Kao A, et al.: Outbreak of coccidioidomycosis in Washington state residents returning from Mexico. Clin Infect Dis 2000, 30:61–64.
Pappagianis D: Epidemiology of coccidioidomycosis. Curr Top Med Mycol 1988, 2:199–238.
Ogiso A, Ito M, Koyama M, et al.: Pulmonary coccidioidomycosis in Japan: case report and review. Clin Infect Dis 1997, 25:1260–261.
Galgiani JN: Coccidioidomycosis. West J Med 1993, 159:153–171.
Schneider E, Hajjeh RA, Spiegel RA, et al.: A coccidioidomycosis outbreak following the Northridge, Calif, earthquake. JAMA 1997, 277:904–908.
Coccidioidomycosis in travelers returning from Mexico-Pennsylvania, 2000. MMWR Morb Mortal Wkly Rep 2000, 49:1004–1006.
Einstein HE, Johnson RH: Coccidioidomycosis: new aspects of epidemiology and therapy. Clin Infect Dis 1993, 16:349–356.
Leake JAD, Mosley DG, England B, et al.: Risk factors for acute symptomatic coccidioidomycosis among elderly persons in Arizona, 1996–1997. Clin Infect Dis 2000, 181:1435–1440.
Catanzaro A: Pulmonary coccidioidomycosis. Med Clin North Am 1980, 64:461–473.
Batra P: Pulmonary coccidioidomycosis. J Thorac Imaging 1992, 7:29–38.
Sarosi GA, Parker JD, Doto IL, et al.: Chronic pulmonary coccidioidomycosis. N Engl J Med 1970, 283:25–329.
Read CT: Coin lesion, pulmonary: in the southwest (solitary pulmonary nodules). Ariz Med 1972, 29:775–781.
Chitkara YK: Evaluation of cultures of percutaneous core needle biopsy specimens in the diagnosis of pulmonary nodules. Am J Clin Pathol 1997, 107:224–228.
Arsura El, Kilgore WB: Miliary coccidioidomycosis in the immunocompetent. Chest 2000, 117:404–409.
Warlick MA, Quan SF, Sobonya RE: Rapid diagnosis of pulmonary coccidioidomycosis. Cytologic v potassium hydroxide preparations. Arch Intern Med 1983, 143:723–725.
DiTomasso JP, Ampel NM, Sobonya RE, et al.: Bronchoscopic diagnosis of pulmonary coccidioidomycosis. Comparison of cytology, culture, and transbronchial biopsy. Diagn Microbiol Infect Dis 1994, 18:83–87.
Raab SS, Silverman JF, Zimmerman KG: Fine-needle aspiration biopsy of pulmonary coccidioidomycosis. Spectrum of cytologic findings in 73 patients. Am J Clin Pathol 1993, 99:582–587.
Chen KTK: Cytodiagnostic pitfalls in pulmonary coccidioidomycosis. Diagn Cytopathol 1995, 12:177–180.
Pappagianis D, Zimmer BL: Serology of coccidioidomycosis. Clin Microbiol Rev 1990, 3:247–268.
Martins TB, Jaskowski TD, Mouritsen CL, et al.: Comparison of commercially available enzyme immunoassay with traditional serological tests for detection of antibodies to Coccidioides immitis. J Clin Microbiol 1995, 33:940–943.
Zartarian M, Peterson EM, de la Maza LM: Detection of antibodies to Coccidioides immitis by enzyme immunoassay. Am J Clin Pathol 1997, 107:148–153.
Kaufman L, Sekhon AS, Moledina N, et al.: Comparative evaluation of commercial Premier EIA and microimmunodiffusion and complement fixation test for Coccidioides immitis antibodies. J Clin Microbiol 1995, 33:618–619.
Johnson SM, Pappagianis D: The coccidioidal complement fixation and immunodiffusion-complement fixation antigen is a chitinase. Infect Immun 1992, 60:2588–2592.
Zimmermann CR, Johnson SM, Martens GW, et al.: Cloning and expression of the complement fixation antigen-chitinase of Coccidioides immitis. Infect Immun 1996, 64:4967–4975.
Yang C, Zhu Y, Magee DM, et al.: Molecular cloning and characterization of the Coccidioides immitis complement fixation/ chitinase antigen. Infect Immun 1996, 64:1992–1997.
Yang MC, Magee DM, Cox RA: Mapping of a Coccidioides immitis-specific epitope that reacts with complement-fixing antibody. Infect Immun 1997, 65:4068–4074.
Johnson SM, Zimmermann CR, Pappagianis D: Use of a recombinant Coccidioides immitis complement fixation antigen- chitinase in conventional serological assays. J Clin Microbiol 1996, 34:3160–3164.
Galgiani JN, Ampel NM, Catanzaro A, et al.: Practice guidelines for the treatment of coccidioidomycosis. Clin Infect Dis 2000, 30:658–661.Practice guidelines for the treatment of coccidioidomycosis that were developed by members of the National Institutes of Allergy and Infectious Diseases Mycoses Study Group. The strength of variousrecommendations have been graded according to the quality and quantity of the supporting data.
Woods CW, Mcrill C, Plikaytis BD, et al.: Coccidioidomycosis in human immunodeficiency virus-infected persons in Arizona, 1994–1997: incidence, risk factors, and prevention. Clin Infect Dis 2000, 181:1428–1434.
Catanzaro A, Galgiani JN, Levine BE, et al.: Fluconazole in the treatment of chronic pulmonary and nonmeningeal disseminated coccidioidomycosis. Am J Med 1995, 98:249–256.
Diaz M, Puente R, de Hoyos LA, et al.: Itraconazole in the treatment of coccidioidomycosis. Chest 1991, 100:682–684.
Galgiani JN, Catanzaro A, Cloud GA, et al.: Comparison of oral fluconazole and itraconazole for progressive, nonmeningeal coccidioidomycosis. Ann Intern Med 2000, 133:676–686.This randomized, double-blind trial comparing oral fluconazole and itraconazole for progressive nonmeningeal coccidioidomycosis demonstrated that neither drug showed statistically superior efficacy, although there was a trend toward slightly greater efficacy with itraconazole.
Polesky A, Kirsch CM, Snyder LS, et al.: Airway coccidioidomycosis- report of cases and review. Clin Infect Dis 1999, 28:1273–1280.
Winn RE, Johnson R, Galgiani JN, et al.: Cavitary coccidioidomycosis with fungus ball formation. Diagnosis by fiberoptic bronchoscopy with coexistence of hyphae and spherules. Chest 1994, 105:412–416.
Oldfield EC 3d, Bone WD, Martin CR, et al.: Prediction of relapse after treatment of coccidioidomycosis. Clin Infect Dis 1997, 25:1205–1210. Patients who do not develop a positive C. immitis skin test result and those with an initial complement fixation titer greater than 1:256 have a greater chance of relapse after completion of therapy.
Pappagianis D: Evaluation of the protective efficacy of the killed Coccidioides immitis spherule vaccine in humans. The Valley Fever Vaccine Study Group. Am Rev Respir Dis 1993, 148:656–660.
Cox RA, Magee DM: Protective immunity in coccidioidomycosis. Res Immunol 1998, 149:417–428.
Zimmermann CR, Johnson SM, Martens GW, et al.: Protection against lethal murine coccidioidomycosis by a soluble vaccine from spherules. Infect Immun 1998, 66:2342–2345.
Peng T, Orsborn KL, Orbach MJ, et al.: Proline-rich vaccine candidate antigen of Coccidioides immitis: conservation among isolates and differential expression with spherule maturation. J Infect Dis 1999, 179:518–521.
Abuodeh RO, Shubitz LF, Siegel E, et al.: Resistance to Coccidioides immitis in mice after immunization with recombinant protein or a DNA vaccine of a proline-rich antigen. Infect Immun 1999, 67:2935–2940.
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Lin, J., Hamill, R.J. Coccidioidomycosis pulmonary infection. Curr Infect Dis Rep 3, 274–278 (2001). https://doi.org/10.1007/s11908-001-0030-7
Issue Date:
DOI: https://doi.org/10.1007/s11908-001-0030-7